DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for type 1 diabetes mellitus — screening already-approved drugs against its 45-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleType 1 diabetes mellitus maps to a 45-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedSunitinibApproved drug
Structures already discussed alongside type 1 diabetes mellitus in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
KIT kinase domain — Sunitinib has a real, experimentally solved structure in complex with this target (PDB 3G0E, 1.6 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet b49drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3G0E · 1.6 Å · ligand Sunitinib (B49). Experimental structure, not a prediction.
What the evidence adds up to
A 2017 review of neonatal hypoglycaemia discusses the condition in preterm and growth-restricted infants, noting that 30–60% of these high-risk neonates are hypoglycaemic and require immediate intervention. The review does not address type 1 diabetes mellitus. A 2009 article on type 1 diabetes states that the disease affects over 1.4 million people in the US, has a strong hereditary component, and involves autoimmunity. It mentions that new technologies have allowed early recognition of disease and the potential for prevention trials and early insulin treatment, but provides no trial results or efficacy data for any intervention.
A 2013 case report describes a patient with type 2 diabetes who developed severe hypoglycaemia after treatment with sunitinib, a tyrosine kinase inhibitor used for metastatic renal cell carcinoma. Blood glucose levels normalised two weeks after sunitinib was stopped. The authors note that sunitinib can be regarded as having an antidiabetic effect, but state that life-threatening hypoglycaemia is rare and that the underlying mechanism is not completely understood. This is a single case in type 2 diabetes, not type 1.
No abstract provides evidence for any drug that prevents, reverses, or alters the course of type 1 diabetes. The 2009 article mentions prevention trials as a future possibility but gives no results. The 2017 review is about neonatal hypoglycaemia, not type 1 diabetes. The 2013 case report involves a different disease and a different diabetes type. What is missing is any completed trial showing that a repurposed drug changes outcomes in type 1 diabetes, any patient stratification strategy, and any funding for such trials.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Translational Pediatrics · 2017 · 28 citations · open access
Type 1 diabetes: where are we in 2017?
AbstractAbstract: Glucose, like oxygen, is of fundamental importance for any living being and it is the major energy source for the fetus and the neonate during gestation. The placenta ensures a steady supply of glucose to the fetus, while birth marks a sudden change in substrate delivery and a major change in metabolism. Hypoglycemia is one of the most common pathologies encountered in the neonatal intensive care unit and affects a wide range of neonates. Preterm, small for gestational age (GA) and intra-uterine growth restricted neonates are especially vulnerable due to their lack of metabolic reserves and associated co-morbidities. Nearly 30–60% of these high-risk infants are hypoglycemic and require immediate intervention. Preterm neonates are uniquely predisposed to developing hypoglycemia and its associated complications due to their limited glycogen and fat stores, inability to generate new glucose using gluconeogenesis pathways, have higher metabolic demands due to a relatively larger brain size, and are unable to mount a counter-regulatory response to hypoglycemia. In this review we will discuss the epidemiology; pathophysiology; clinical presentation; management and neurodevelopmental outcomes in affected infants and summarize evidence to develop a rational and scientific approach to this common problem.
Journal of Oncology Pharmacy Practice · 2013 · 19 citations
Sunitinib-induced severe hypoglycemia in a diabetic patient
AbstractINTRODUCTION: Sunitinib is an oral inhibitor of tyrosine kinase that was used for the treatment of mRCC. The general side effects are fatigue, asthenia, diarrhea, mucositis, nausea, vomiting, skin changes, hypertension, hypothyroidism and hematologic side effects. In addition, sunitinib-induced hypoglycemia has also been reported. There are limited number of case reports related to sunitinib-induced hypoglycemia. CASE PRESENTATION: In this case report, we have presented a patient with type 2 diabetes mellitus (DM) with emerging severe hypoglycemia after sunitinib treatment. It was shown that blood glucose levels were normalized two weeks after the interruption of sunitinib. CONCLUSION: Although the underlying mechanism of sunitinib-induced hypoglycemia is not completely understood, sunitinib can be regarded to have an antidiabetic effect. In the literature, there are some reports about sunitinib/other TKI induced hypoglycemia; however, life threatening hypoglycemia is rare. There is no case report of severe hypoglycemia due to imatinib; however, there are two case reports with severe hypoglycemia due to sunitinib treatment. Symptomatic hypoglycemic episodes due to sunitinib may lead to hospital admission. Diabetic patients may develop severe hypoglycaemia and it should be kept in mind that the discontinuation of antihyperglycemic treatment may be required. Therefore, blood glucose levels should be closely monitored in diabetic patients with mRCC during sunitinib therapy.
US Endocrinology · 2009 · 1 citations · open access
Type 1 Diabetes—Pathogenesis, Prediction, and Prevention
AbstractType 1 diabetes affects over 1.4 million people in the US, with a rising incidence in many western nations. It is clear that there is a strong hereditary component and that autoimmunity plays a large role in disease pathogenesis. In the last two decades novel technologies have been developed to study the genetics, biochemistry, and molecular pathology of type 1 diabetes. These, in turn, have allowed for early recognition of disease as well as the potential for prevention trials and early insulin treatment. This article highlights the prediction of type 1 diabetes risk and developing immunotherapeutic concepts.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
